Dr. Fariba Navid, MD
Claim this profileChildren's Hospital Los Angeles
About Fariba Navid, MD
Education:
- Earned an MD from Tulane Medical School, New Orleans, Louisiana.
- Completed a Clinical Fellowship in Pediatric Oncology at the National Cancer Institute, Bethesda, MD.
Experience:
- Serves as Assistant Director of the Clinical Trials Program and COG Phase I & Pilot Consortium at Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles (CHLA) since September 2016.
- Holds the position of Associate Professor of Clinical Pediatrics at the Keck School of Medicine, University of Southern California.
- Has extensive experience in research and pediatric early-phase drug development, including previous work at St. Jude Children's Research Hospital.
Area of expertise
Cancer
Fariba Navid, MD has run 22 trials for Cancer. Some of their research focus areas include:
Osteosarcoma
Fariba Navid, MD has run 16 trials for Osteosarcoma. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital Los Angeles
Children's Hospital Of Los Angeles
Clinical Trials Fariba Navid, MD is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting
1 award
Phase 1 & 2
13 criteria
NK Cells + Chemotherapy
for Sarcoma
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with childhood sarcomas that have relapsed or not responded to prior therapies. The goals of this study are: * To determine the safety and efficacy of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to the pediatric sarcoma salvage chemotherapeutic regimen gemcitabine/docetaxel (GEM/DOX) for treatment of relapsed and refractory pediatric sarcomas To determine the 6-month progression free survival achieved with this treatment in patients within cohorts of relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma. * To identify toxicities related to treatment with GEM/DOX + TGFβi expanded NK cells Participants will receive study drugs that include chemotherapy and NK cells in cycles; each cycle is 21 days long and you can receive up to 8 cycles. * Gemcitabine (GEM): via IV on Days 1 and 8 * Docetaxel (DOX): via IV on Day 8 * Prophylactic dexamethasone: Day 7-9 to prevent fluid retention and hypersensitivity reaction * Peg-filgrastim (PEG-GCSF) or biosimilar: Day 9 to help your white blood cell recover and allow more chemotherapy to be given * TGFβi NK cells: via IV on Day 12
Recruiting
1 award
Phase 1 & 2
More about Fariba Navid, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Fariba Navid, MD has experience with
- Larotrectinib
- Palbociclib
- Erdafitinib
- Selpercatinib
- Tipifarnib
- Vemurafenib
Breakdown of trials Fariba Navid, MD has run
Cancer
Osteosarcoma
Solid Tumors
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Fariba Navid, MD specialize in?
Fariba Navid, MD focuses on Cancer and Osteosarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Fariba Navid, MD currently recruiting for clinical trials?
Yes, Fariba Navid, MD is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Fariba Navid, MD has studied deeply?
Yes, Fariba Navid, MD has studied treatments such as Larotrectinib, Palbociclib, Erdafitinib.
What is the best way to schedule an appointment with Fariba Navid, MD?
Apply for one of the trials that Fariba Navid, MD is conducting.
What is the office address of Fariba Navid, MD?
The office of Fariba Navid, MD is located at: Children's Hospital Los Angeles, Los Angeles, California 90027 United States. This is the address for their practice at the Children's Hospital Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.